Form 4: Elevation Oncology CFO Tammy Furlong Reports Stock Transactions

Tammy Furlong, CFO of Elevation Oncology, reports the acquisition and disposal of common stock and derivative securities, including stock options and restricted stock units, on February 15, 2025.

Summary

• On February 15, 2025, Tammy Furlong, the CFO of Elevation Oncology, engaged in transactions involving the company's stock.
• These transactions included the acquisition of 9,375 shares of common stock through the vesting of restricted stock units (RSUs) and the acquisition of 300 shares of common stock through the vesting of restricted stock units.
• Furlong also disposed of 2,780 shares of common stock to cover tax obligations at a price of $0.6717 per share and disposed of 89 shares of common stock to cover tax obligations at a price of $0.6717 per share.
• Following these transactions, Furlong directly owns 8,216 shares of common stock.
• Additionally, Furlong acquired a stock option to purchase 275,000 shares of common stock at an exercise price of $0.6717, which vests over time.
• She also holds 2,400 and 28,125 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected as part of the executive compensation plan. There are no indications of significant positive or negative developments.

Positives

• The acquisition of shares through RSU vesting indicates confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax obligations, while routine, could be perceived negatively if investors interpret it as a lack of confidence, although the amount is small.

Risks

• The vesting schedules of the stock options and RSUs are subject to Furlong's continued service to the Issuer, creating a dependency on her continued employment.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and RSUs suggest a long-term commitment from the CFO.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules, such as the ones described in the document (25% after one year, then monthly or quarterly), are typical in the industry to incentivize long-term performance.
• Comparable companies like Arcus Biosciences or Relay Therapeutics also utilize stock options and RSUs as part of their executive compensation packages.

Stakeholder Impact

• The transactions have a minor impact on shareholders by slightly diluting the share base through the issuance of new shares upon RSU vesting and option exercise.

Key Dates